查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2014827

植入式藥物輸送裝置市場：依產品類型、技術、應用和最終用戶分類－2026-2032年全球市場預測

Implantable Drug Delivery Device Market by Product Type, Technology, Application, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 183 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，植入式藥物輸送裝置市值將達到 232.9 億美元，到 2026 年將成長至 252 億美元，到 2032 年將達到 444.7 億美元，複合年成長率為 9.67%。

主要市場統計數據
基準年 2025 232.9億美元
預計年份：2026年 252億美元
預測年份 2032 444.7億美元
複合年成長率 (%) 9.67%

策略性和背景性的引入，不斷提升臨床意義和跨學科創新，推動植入式藥物傳遞裝置的發展。

植入式藥物輸送裝置正在改變我們治療患者的方式，它能夠在多個臨床領域實現精準、持續和局部的藥物傳遞。材料科學、微型化和先進藥物製劑技術的融合正在推動新型裝置架構的出現，這些架構能夠降低劑量差異、提高患者依從性並擴大治療範圍。在過去十年間，臨床醫生和研發人員已從單一用途的植入轉向結合感測、控制和生物相容性設計的系統，以應對慢性疾病和標靶腫瘤治療。

監管澄清、數位化整合和生物材料創新方面的重大變革正在重新定義植入式藥物輸送裝置的開發和普及。

植入式藥物輸送裝置的格局正在經歷一場變革，這主要得益於數位控制、生物材料創新和以患者為中心的護理模式的融合。首先，微晶片和電子機械控制系統的整合實現了可程式設計給藥和遠端劑量調節，從而改變了人們對個人化醫療和臨床管理的預期。其次，生物可分解聚合物和滲透技術的進步減少了消毒程序的需求，提高了安全性和病人接受度。第三，隨著基於結果的合約和價值論證變得越來越重要，研發重點正轉向可衡量的藥物依從性改善和住院率降低。

分析 2025 年美國關稅政策轉變對植入式醫療設備供應鏈和製造選擇的累積營運和策略影響。

2025年美國關稅趨勢對植入式藥物輸送裝置的製造商和供應商的供應鏈提出了關鍵性考量，推動了整個價值鏈籌資策略和成本結構的變革。特定零件關稅的提高促使製造商重新評估其供應商組合，加快近岸外包，並重新談判長期合約以確保關鍵聚合物、微電子元件和精密模塑零件的供應。因此，採購團隊已將重點重新轉向供應商多元化、庫存彈性以及合格的第二供應商策略，以降低單一來源風險。

將產品類型、臨床應用、最終用戶環境、底層技術、商業化途徑和證據要求聯繫起來的策略性細分洞察。

基於細分市場的洞察揭示了不同產品類型、應用、終端用戶和底層技術中存在的微妙機會和限制因素。按產品類型分類，研發重點涵蓋各種輸液泵、微晶片植入和滲透泵，以及避孕植入物和藥物釋放型支架。在藥物釋放型支架方面，冠狀動脈和周邊血管應用的差異決定了臨床定位和介入治療流程；而輸液泵的創新則延伸至化療泵、胰島素泵和鎮痛泵，每種泵都有其獨特的監管、給藥和耐久性要求。按應用領域分類，循環系統、避孕、糖尿病、神經病學、腫瘤學和疼痛管理領域需要針對特定應用客製化的設備特性，例如心臟植入的血流動力學兼容性和血栓症減少，以及慢性疼痛和腫瘤治療應用中的精確可程式設計給藥和生物相容性儲液器。

全面深入的區域分析，闡述法律規範、報銷環境和臨床生態系統如何影響全球市場對醫療設備的採用。

區域趨勢塑造了植入式藥物輸送裝置的監管路徑、報銷方式和創新生態系統。美洲地區擁有強大的臨床試驗、創投和先進製造生態系統，重點在於快速評估可程式設計植入在真實臨床環境中的應用。該地區的監管機構強調上市後監測和互通性標準，以支持數據驅動的證據產生。歐洲、中東和非洲（EMEA）地區的市場格局較為複雜，監管協調和國家報銷模式的推進既帶來了機遇，也帶來了准入挑戰，迫使製造商採取差異化的打入市場策略，並根據當地價值標準調整定價。在這些市場，與當地臨床意見領袖和衛生技術評估機構合作對於確保手術應用和獲得支付方的支持至關重要。

透過整合技術、證據和服務生態系統，打造領導企業，並具備關鍵的企業能力和策略行動，脫穎而出。

該領域的主要企業具備涵蓋材料科學、器材工程、臨床開發以及支持病人參與的服務模式的綜合能力。市場參與企業將專有的給藥技術與強大的上市後數據收集和分析能力相結合，從而在向臨床醫生和支付方展示實際價值方面獲得競爭優勢。醫療設備製造商、專科藥物開發商和數位醫療服務提供者之間的策略夥伴關係，能夠提供兼顧劑量準確性和用藥依從性監測的綜合解決方案。同時，擁有醫療級製程專業知識的契約製造製造商有助於擴大生產規模並控制成本。

為開發商和相關人員提供具體策略建議，以加速植入式醫療設備的普及應用，確保報銷，並增強供應鏈的韌性。

產業領導者應優先採取一系列切實可行的步驟，以加速產品推廣應用並降低商業化風險。首先，研發藍圖應與支付者和醫療服務提供者重視的臨床終點保持一致，並投資產生可操作的證據，以證明藥物依從性、臨床療效和資源利用率的改善。這種方法有助於明確價值溝通，並推動醫保報銷的討論。其次，透過供應商多元化、選擇關鍵零件的替代來源以及選擇性近岸外包來最佳化供應鏈，從而降低貿易政策變化帶來的風險。第三，推行模組化平台策略，在維持擴充性生產流程的同時，實現產品在心臟病、糖尿病和腫瘤等應用領域的客製化。

這種透明的調查方法詳細介紹了混合方法、專家合作和證據整合，以期對植入式醫療設備的創新產生平衡的見解。

本分析採用混合研究途徑，結合了定性專家訪談、監管指南整合以及對同行評審的臨床文獻和技術標準的系統性回顧。主要資料來源包括對臨床研究人員、器材工程師、採購負責人和監管專家的結構化訪談，以收集有關安全性、植入流程和上市後監測的經驗性見解。次要資訊來源包括公開的監管指南文件、材料和微電子學白皮書以及報告器械安全性、生物相容性和臨床結果的同行評審研究，以確保與最新證據保持一致。

最終的整合凸顯了技術、證據和營運韌性的融合，這是決定植入式藥物傳輸設備未來主導的關鍵因素。

總之，植入式藥物輸送裝置已進入成熟階段，其特點是整合了數位化控制技術、改進了生物材料，並建立了強調長期患者管理的醫療服務模式。這些因素的融合正在重塑循環系統、糖尿病、腫瘤和疼痛管理等領域的臨床路徑，使治療方案更加個人化、依從性更高、療效更佳。同時，供應鏈的韌性、複合產品監管規定的明確性以及可驗證的實際應用價值仍然是商業性成功的關鍵要素。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 市場進入策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：植入式藥物輸送裝置市場：依產品類型分類

  • 避孕植入
  • 藥物釋放型支架
    • 冠狀動脈支架
    • 外周支架
  • 點滴幫浦
    • 化療泵
    • 胰島素幫浦
    • 疼痛管理泵
  • 微晶片植入
  • 滲透泵浦

第9章：植入式藥物輸送裝置市場：依技術分類

  • 可生物分解聚合物
  • 機械幫浦
  • 基於微晶片
    • 電子機械泵浦
    • MEMS系統
  • 滲透泵浦

第10章：植入式藥物輸送裝置市場：依應用領域分類

  • 循環系統
  • 避孕
  • 糖尿病
  • 神經病學
  • 腫瘤學
  • 疼痛管理

第11章：植入式藥物輸送裝置市場：依最終用戶分類

  • 居家醫療
  • 醫院
  • 專科診所

第12章：植入式藥物輸送裝置市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章：植入式藥物輸送裝置市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章：植入式藥物輸送裝置市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章：美國植入式藥物傳輸裝置市場

第16章：中國植入式藥物傳輸裝置市場

第17章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Abbott Laboratories
  • Becton, Dickinson and Company
  • Boston Scientific Corporation
  • CeQur SA
  • Debiotech SA
  • Enable Injections, Inc.
  • Insulet Corporation
  • Intarcia Therapeutics, Inc.
  • Medtronic plc
  • MicroCHIPS Biotechnology, Inc.
  • Roche Holding AG
  • Sensile Medical AG
  • SteadyMed Ltd.
  • Tandem Diabetes Care, Inc.
  • Terumo Corporation
  • Valeritas Holdings, Inc.
  • West Pharmaceutical Services, Inc.
  • Ypsomed Holding AG
Product Code: MRR-43127F7279DC

The Implantable Drug Delivery Device Market was valued at USD 23.29 billion in 2025 and is projected to grow to USD 25.20 billion in 2026, with a CAGR of 9.67%, reaching USD 44.47 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 23.29 billion
Estimated Year [2026] USD 25.20 billion
Forecast Year [2032] USD 44.47 billion
CAGR (%) 9.67%

A strategic and contextual introduction to the rising clinical relevance and multidisciplinary innovation driving implantable drug delivery device evolution

Implantable drug delivery devices are reshaping therapeutic pathways by enabling precise, continuous, and localized administration of medicines across multiple clinical domains. The intersection of materials science, miniaturized electronics, and advanced drug formulations has catalyzed new device architectures that reduce dosing variability, enhance patient adherence, and expand therapeutic windows. Over the last decade, clinicians and developers have moved beyond single-purpose implants toward systems that combine sensing, controlled release, and biocompatible design to address chronic conditions and targeted oncology interventions.

Clinical stakeholders increasingly prioritize devices that reduce systemic exposure while maintaining efficacy, and regulatory bodies have responded with clearer guidance on combination products and real-world performance evidence. Meanwhile, technology transfers and cross-disciplinary collaboration between medtech engineers and pharmaceutical formulation scientists have accelerated iterative improvements in device longevity, safety profiling, and manufacturability. As a result, care pathways are evolving to embed implantable solutions alongside pharmacotherapy and biologics, creating opportunities for differentiated patient experience, improved adherence metrics, and new commercial models aligned with outcomes-based reimbursement.

Key transformative shifts in regulatory clarity, digital integration, and biomaterials innovation redefining implantable drug delivery device development and adoption

The landscape for implantable drug delivery devices has undergone transformative shifts driven by convergence of digital control, biomaterials innovation, and patient-centric care models. First, the integration of microchip and electromechanical control systems allows programmable dosing and remote titration, which has altered expectations for personalization and clinician oversight. Second, advances in biodegradable polymers and osmotic technologies have reduced the need for retrieval procedures, improving safety profiles and patient acceptance. Third, the increasingly prominent role of outcome-based contracting and value demonstration has redirected R&D priorities toward measurable adherence improvements and reduced hospital utilization.

Concurrently, regulatory frameworks have matured to better address combination products, digital health components, and post-market surveillance obligations. This regulatory clarity, together with expanding interoperability standards, permits device makers to incorporate data-driven features that support remote monitoring and longitudinal evidence generation. Moreover, reimbursement strategies are shifting to recognize the long-term cost offsets of improved adherence and reduced complication rates, prompting health systems and payers to pilot innovative contracting models. Together, these trends are driving a transition from point-solution implants to integrated therapeutic platforms that deliver clinical value across the patient journey.

Analyzing the cumulative operational and strategic impact of United States tariff policy shifts in 2025 on implantable device supply chains and manufacturing choices

Tariff dynamics in the United States during 2025 introduced significant supply chain considerations for manufacturers and suppliers of implantable drug delivery devices, altering sourcing strategies and cost structures across the value chain. Increased duties on certain components incentivized manufacturers to reassess supplier portfolios, accelerate nearshoring initiatives, and renegotiate long-term contracts to secure critical polymers, microelectronics, and precision-molded parts. As a result, procurement teams placed renewed emphasis on supplier diversification, inventory resilience, and qualified second-source strategies to mitigate single-origin risk.

In response to tariff-driven pressures, many organizations reprioritized capital allocation toward domestic manufacturing capacity and automation to contain variable cost exposure and reduce lead-time volatility. These investments were coupled with intensified supplier development programs that emphasize quality systems alignment, regulatory readiness, and traceability. Additionally, commercial teams reviewed pricing models and contracting terms to preserve margin while maintaining market access, and clinical supply planners tightened change-control protocols for any component substitutions. Crucially, the policy environment highlighted the need for robust scenario planning and dynamic cost modeling to navigate future trade policy shifts without compromising product continuity or patient access.

Strategic segmentation insights that connect product types, clinical applications, end-user environments, and enabling technologies to commercialization pathways and evidence needs

Segmentation-based insights reveal nuanced opportunities and constraints across product types, applications, end users, and enabling technologies. Based on product type, development attention concentrates on contraceptive implants and drug eluting stents alongside a diverse set of infusion pumps, microchip implants, and osmotic pumps; within drug eluting stents, a distinction between coronary and peripheral stents informs clinical positioning and interventional workflows, while infusion pump innovation spans chemotherapy pumps, insulin pumps, and pain management pumps, each with distinct regulatory, dosing, and durability requirements. Based on application, cardiology, contraception, diabetes, neurology, oncology, and pain management each demand tailored device attributes, from hemodynamic compatibility and thrombosis mitigation for cardiac implants to precise, programmable dosing and biocompatible reservoirs for chronic pain and oncology use cases.

Based on end user, deployment pathways differ markedly between home care, hospitals, and specialty clinics, which affects device service models, training requirements, and post-implant monitoring strategies; home care adoption favors devices with simplified maintenance and remote support, while hospitals and specialty clinics require integration with procedural workflows and sterilization protocols. Based on technology, material and platform choices such as biodegradable polymers, mechanical pumps, microchip-based solutions, and osmotic pumps determine longevity, biocompatibility, and upgradability; within microchip-based approaches, electromechanical pumps and MEMS systems offer differing balances of miniaturization, power consumption, and programmability that influence clinical applicability. Taken together, these segmentation lenses enable developers to prioritize feature sets, clinical evidence generation, and commercialization pathways that align with the nuanced needs of each therapeutic and care-delivery context.

Comprehensive regional insights describing how regulatory frameworks, reimbursement environments, and clinical ecosystems shape device adoption across global markets

Regional dynamics shape regulatory pathways, reimbursement approaches, and innovation ecosystems for implantable drug delivery devices. The Americas demonstrate a strong ecosystem for clinical trials, venture investment, and advanced manufacturing, with an emphasis on rapid evaluation of programmable and digital-enabled implants in real-world settings; regulatory bodies in this region emphasize post-market surveillance and interoperability standards that support data-driven evidence generation. Europe, Middle East & Africa presents a heterogeneous landscape where regulatory harmonization efforts and national reimbursement models create both opportunities and access challenges, prompting manufacturers to adopt differentiated market entry strategies and adapt pricing to local value thresholds. In these markets, collaboration with regional clinical opinion leaders and health technology assessment bodies is critical to secure surgical adoption and payer support.

Asia-Pacific encompasses diverse markets with growing surgical volumes and rapidly expanding diabetes and oncology patient populations, which drives demand for scalable manufacturing and cost-effective device variants. Governments and private payers across the region are increasingly receptive to innovations that reduce hospital stays and improve chronic disease management, but successful commercialization often requires local regulatory know-how and supply chain localization. Across all regions, cross-border partnerships, regulatory intelligence, and localized evidence generation remain essential to translate clinical innovation into sustainable adoption and to tailor service models that meet varying healthcare infrastructure requirements.

Key corporate capabilities and strategic behaviors that differentiate leaders in implantable drug delivery devices through integrated technology, evidence, and service ecosystems

Leading companies in this space are characterized by integrated capabilities spanning materials science, device engineering, clinical development, and service models that support long-term patient engagement. Market participants that combine proprietary delivery technologies with robust post-market data capture and analytics gain a competitive edge in demonstrating real-world value to clinicians and payers. Strategic partnerships between device manufacturers, specialty pharmaceutical developers, and digital health providers enable bundled solutions that address both dosing precision and adherence monitoring, while contract manufacturers with medical-grade process expertise support scale-up and cost containment.

Moreover, companies prioritizing regulatory alignment and early engagement with health authorities reduce time-to-market friction for combination products and digital-enabled implants. Competitive differentiation also emerges from intellectual property portfolios that protect unique reservoir designs, release kinetics, and control algorithms. In parallel, firms that invest in clinician education, comprehensive training programs, and streamlined service logistics tend to achieve faster procedural uptake and higher patient satisfaction. Ultimately, sustainable leadership requires not only a compelling device but an ecosystem of aftercare support, evidence generation, and flexible commercialization models that respond to evolving payer and provider expectations.

Actionable strategic recommendations for developers and stakeholders to accelerate adoption, secure reimbursement, and strengthen supply chain resiliency for implantable devices

Industry leaders should prioritize a set of actionable initiatives to accelerate adoption and de-risk commercialization. First, align R&D roadmaps with clinical endpoints that payers and providers value, and invest in pragmatic evidence generation that demonstrates improvements in adherence, clinical outcomes, and resource utilization; this approach enables clearer value communication and supports reimbursement discussions. Second, optimize supply chains through supplier diversification, qualification of alternate sources for critical components, and selective nearshoring to reduce exposure to trade policy fluctuations. Third, pursue modular platform strategies that allow product customization across applications-such as cardiac, diabetes, and oncology-while maintaining scalable manufacturing processes.

Additionally, integrate digital monitoring and telemetry to support remote titration and longitudinal safety monitoring, and establish robust cybersecurity and interoperability practices as a foundational capability. Engage early with regulatory authorities to clarify expectations for combination products and digital components, and design post-market evidence plans that meet both clinical and payer needs. Finally, build clinician-facing education and service programs to reduce procedural friction and support patient adherence; coordinated engagement with health systems, opinion leaders, and patient advocacy groups will facilitate smoother adoption and create advocates who can validate clinical utility.

Transparent research methodology detailing mixed-methods approaches, expert engagement, and evidence synthesis used to produce balanced insights on implantable device innovation

This analysis draws on a mixed-methods research approach combining qualitative expert interviews, regulatory guidance synthesis, and a systematic review of peer-reviewed clinical literature and technical standards. Primary inputs included structured interviews with clinical investigators, device engineers, procurement officers, and regulatory specialists to capture experiential insights on safety, implantation workflows, and post-market surveillance. Secondary inputs comprised public regulatory guidance documents, white papers on materials and microelectronics, and peer-reviewed studies reporting device safety, biocompatibility, and clinical outcomes to ensure alignment with current evidence.

Where appropriate, triangulation methods reconciled differences between stakeholder perspectives and published data to provide balanced conclusions. The methodology also incorporated technology readiness assessments and supply chain risk mapping to reflect operational realities, and scenario analysis to examine the implications of policy shifts. Throughout the research process, emphasis was placed on transparent inclusion criteria for literature, rigorous validation of interview findings, and documentation of methodological limitations to support reproducibility and informed interpretation by decision-makers.

Conclusive synthesis emphasizing the convergence of technology, evidence, and operational resilience as determinants of future leadership in implantable drug delivery devices

In conclusion, implantable drug delivery devices are entering a maturation phase characterized by integration of digital controls, improved biomaterials, and service models that emphasize long-term patient management. These converging forces are reshaping clinical pathways in cardiology, diabetes, oncology, and pain management by enabling more personalized, adherent, and efficient therapies. At the same time, supply chain resilience, regulatory clarity for combination products, and demonstrable real-world value remain essential enablers of commercial success.

As stakeholders navigate tariff dynamics, regional regulatory heterogeneity, and evolving payer expectations, strategic focus on modular platforms, evidence generation aligned with clinical and economic endpoints, and operational agility will determine which organizations convert technological potential into durable market leadership. Ultimately, success depends on orchestrating cross-disciplinary capabilities-from materials and device engineering to clinical strategy and health economics-to deliver safer, more effective, and more accessible implantable therapeutic solutions.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Implantable Drug Delivery Device Market, by Product Type

  • 8.1. Contraceptive Implants
  • 8.2. Drug Eluting Stents
    • 8.2.1. Coronary Stents
    • 8.2.2. Peripheral Stents
  • 8.3. Infusion Pumps
    • 8.3.1. Chemotherapy Pumps
    • 8.3.2. Insulin Pumps
    • 8.3.3. Pain Management Pumps
  • 8.4. Microchip Implants
  • 8.5. Osmotic Pumps

9. Implantable Drug Delivery Device Market, by Technology

  • 9.1. Biodegradable Polymers
  • 9.2. Mechanical Pumps
  • 9.3. Microchip Based
    • 9.3.1. Electromechanical Pumps
    • 9.3.2. MEMS Systems
  • 9.4. Osmotic Pumps

10. Implantable Drug Delivery Device Market, by Application

  • 10.1. Cardiology
  • 10.2. Contraception
  • 10.3. Diabetes
  • 10.4. Neurology
  • 10.5. Oncology
  • 10.6. Pain Management

11. Implantable Drug Delivery Device Market, by End User

  • 11.1. Home Care
  • 11.2. Hospitals
  • 11.3. Specialty Clinics

12. Implantable Drug Delivery Device Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Implantable Drug Delivery Device Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Implantable Drug Delivery Device Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Implantable Drug Delivery Device Market

16. China Implantable Drug Delivery Device Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. Abbott Laboratories
  • 17.6. Becton, Dickinson and Company
  • 17.7. Boston Scientific Corporation
  • 17.8. CeQur SA
  • 17.9. Debiotech S.A.
  • 17.10. Enable Injections, Inc.
  • 17.11. Insulet Corporation
  • 17.12. Intarcia Therapeutics, Inc.
  • 17.13. Medtronic plc
  • 17.14. MicroCHIPS Biotechnology, Inc.
  • 17.15. Roche Holding AG
  • 17.16. Sensile Medical AG
  • 17.17. SteadyMed Ltd.
  • 17.18. Tandem Diabetes Care, Inc.
  • 17.19. Terumo Corporation
  • 17.20. Valeritas Holdings, Inc.
  • 17.21. West Pharmaceutical Services, Inc.
  • 17.22. Ypsomed Holding AG

LIST OF FIGURES

  • FIGURE 1. GLOBAL IMPLANTABLE DRUG DELIVERY DEVICE MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL IMPLANTABLE DRUG DELIVERY DEVICE MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL IMPLANTABLE DRUG DELIVERY DEVICE MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL IMPLANTABLE DRUG DELIVERY DEVICE MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL IMPLANTABLE DRUG DELIVERY DEVICE MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL IMPLANTABLE DRUG DELIVERY DEVICE MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL IMPLANTABLE DRUG DELIVERY DEVICE MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL IMPLANTABLE DRUG DELIVERY DEVICE MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL IMPLANTABLE DRUG DELIVERY DEVICE MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL IMPLANTABLE DRUG DELIVERY DEVICE MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES IMPLANTABLE DRUG DELIVERY DEVICE MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA IMPLANTABLE DRUG DELIVERY DEVICE MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL IMPLANTABLE DRUG DELIVERY DEVICE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL IMPLANTABLE DRUG DELIVERY DEVICE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL IMPLANTABLE DRUG DELIVERY DEVICE MARKET SIZE, BY CONTRACEPTIVE IMPLANTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL IMPLANTABLE DRUG DELIVERY DEVICE MARKET SIZE, BY CONTRACEPTIVE IMPLANTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL IMPLANTABLE DRUG DELIVERY DEVICE MARKET SIZE, BY CONTRACEPTIVE IMPLANTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL IMPLANTABLE DRUG DELIVERY DEVICE MARKET SIZE, BY DRUG ELUTING STENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL IMPLANTABLE DRUG DELIVERY DEVICE MARKET SIZE, BY DRUG ELUTING STENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL IMPLANTABLE DRUG DELIVERY DEVICE MARKET SIZE, BY DRUG ELUTING STENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL IMPLANTABLE DRUG DELIVERY DEVICE MARKET SIZE, BY DRUG ELUTING STENTS, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL IMPLANTABLE DRUG DELIVERY DEVICE MARKET SIZE, BY CORONARY STENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL IMPLANTABLE DRUG DELIVERY DEVICE MARKET SIZE, BY CORONARY STENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL IMPLANTABLE DRUG DELIVERY DEVICE MARKET SIZE, BY CORONARY STENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL IMPLANTABLE DRUG DELIVERY DEVICE MARKET SIZE, BY PERIPHERAL STENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL IMPLANTABLE DRUG DELIVERY DEVICE MARKET SIZE, BY PERIPHERAL STENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL IMPLANTABLE DRUG DELIVERY DEVICE MARKET SIZE, BY PERIPHERAL STENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL IMPLANTABLE DRUG DELIVERY DEVICE MARKET SIZE, BY INFUSION PUMPS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL IMPLANTABLE DRUG DELIVERY DEVICE MARKET SIZE, BY INFUSION PUMPS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL IMPLANTABLE DRUG DELIVERY DEVICE MARKET SIZE, BY INFUSION PUMPS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL IMPLANTABLE DRUG DELIVERY DEVICE MARKET SIZE, BY INFUSION PUMPS, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL IMPLANTABLE DRUG DELIVERY DEVICE MARKET SIZE, BY CHEMOTHERAPY PUMPS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL IMPLANTABLE DRUG DELIVERY DEVICE MARKET SIZE, BY CHEMOTHERAPY PUMPS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL IMPLANTABLE DRUG DELIVERY DEVICE MARKET SIZE, BY CHEMOTHERAPY PUMPS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL IMPLANTABLE DRUG DELIVERY DEVICE MARKET SIZE, BY INSULIN PUMPS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL IMPLANTABLE DRUG DELIVERY DEVICE MARKET SIZE, BY INSULIN PUMPS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL IMPLANTABLE DRUG DELIVERY DEVICE MARKET SIZE, BY INSULIN PUMPS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL IMPLANTABLE DRUG DELIVERY DEVICE MARKET SIZE, BY PAIN MANAGEMENT PUMPS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL IMPLANTABLE DRUG DELIVERY DEVICE MARKET SIZE, BY PAIN MANAGEMENT PUMPS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL IMPLANTABLE DRUG DELIVERY DEVICE MARKET SIZE, BY PAIN MANAGEMENT PUMPS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL IMPLANTABLE DRUG DELIVERY DEVICE MARKET SIZE, BY MICROCHIP IMPLANTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL IMPLANTABLE DRUG DELIVERY DEVICE MARKET SIZE, BY MICROCHIP IMPLANTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL IMPLANTABLE DRUG DELIVERY DEVICE MARKET SIZE, BY MICROCHIP IMPLANTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL IMPLANTABLE DRUG DELIVERY DEVICE MARKET SIZE, BY OSMOTIC PUMPS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL IMPLANTABLE DRUG DELIVERY DEVICE MARKET SIZE, BY OSMOTIC PUMPS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL IMPLANTABLE DRUG DELIVERY DEVICE MARKET SIZE, BY OSMOTIC PUMPS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL IMPLANTABLE DRUG DELIVERY DEVICE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL IMPLANTABLE DRUG DELIVERY DEVICE MARKET SIZE, BY BIODEGRADABLE POLYMERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL IMPLANTABLE DRUG DELIVERY DEVICE MARKET SIZE, BY BIODEGRADABLE POLYMERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL IMPLANTABLE DRUG DELIVERY DEVICE MARKET SIZE, BY BIODEGRADABLE POLYMERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL IMPLANTABLE DRUG DELIVERY DEVICE MARKET SIZE, BY MECHANICAL PUMPS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL IMPLANTABLE DRUG DELIVERY DEVICE MARKET SIZE, BY MECHANICAL PUMPS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL IMPLANTABLE DRUG DELIVERY DEVICE MARKET SIZE, BY MECHANICAL PUMPS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL IMPLANTABLE DRUG DELIVERY DEVICE MARKET SIZE, BY MICROCHIP BASED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL IMPLANTABLE DRUG DELIVERY DEVICE MARKET SIZE, BY MICROCHIP BASED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL IMPLANTABLE DRUG DELIVERY DEVICE MARKET SIZE, BY MICROCHIP BASED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL IMPLANTABLE DRUG DELIVERY DEVICE MARKET SIZE, BY MICROCHIP BASED, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL IMPLANTABLE DRUG DELIVERY DEVICE MARKET SIZE, BY ELECTROMECHANICAL PUMPS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL IMPLANTABLE DRUG DELIVERY DEVICE MARKET SIZE, BY ELECTROMECHANICAL PUMPS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL IMPLANTABLE DRUG DELIVERY DEVICE MARKET SIZE, BY ELECTROMECHANICAL PUMPS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL IMPLANTABLE DRUG DELIVERY DEVICE MARKET SIZE, BY MEMS SYSTEMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL IMPLANTABLE DRUG DELIVERY DEVICE MARKET SIZE, BY MEMS SYSTEMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL IMPLANTABLE DRUG DELIVERY DEVICE MARKET SIZE, BY MEMS SYSTEMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL IMPLANTABLE DRUG DELIVERY DEVICE MARKET SIZE, BY OSMOTIC PUMPS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL IMPLANTABLE DRUG DELIVERY DEVICE MARKET SIZE, BY OSMOTIC PUMPS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL IMPLANTABLE DRUG DELIVERY DEVICE MARKET SIZE, BY OSMOTIC PUMPS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL IMPLANTABLE DRUG DELIVERY DEVICE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL IMPLANTABLE DRUG DELIVERY DEVICE MARKET SIZE, BY CARDIOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL IMPLANTABLE DRUG DELIVERY DEVICE MARKET SIZE, BY CARDIOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL IMPLANTABLE DRUG DELIVERY DEVICE MARKET SIZE, BY CARDIOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL IMPLANTABLE DRUG DELIVERY DEVICE MARKET SIZE, BY CONTRACEPTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL IMPLANTABLE DRUG DELIVERY DEVICE MARKET SIZE, BY CONTRACEPTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL IMPLANTABLE DRUG DELIVERY DEVICE MARKET SIZE, BY CONTRACEPTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL IMPLANTABLE DRUG DELIVERY DEVICE MARKET SIZE, BY DIABETES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL IMPLANTABLE DRUG DELIVERY DEVICE MARKET SIZE, BY DIABETES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL IMPLANTABLE DRUG DELIVERY DEVICE MARKET SIZE, BY DIABETES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL IMPLANTABLE DRUG DELIVERY DEVICE MARKET SIZE, BY NEUROLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL IMPLANTABLE DRUG DELIVERY DEVICE MARKET SIZE, BY NEUROLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL IMPLANTABLE DRUG DELIVERY DEVICE MARKET SIZE, BY NEUROLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL IMPLANTABLE DRUG DELIVERY DEVICE MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL IMPLANTABLE DRUG DELIVERY DEVICE MARKET SIZE, BY ONCOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL IMPLANTABLE DRUG DELIVERY DEVICE MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL IMPLANTABLE DRUG DELIVERY DEVICE MARKET SIZE, BY PAIN MANAGEMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL IMPLANTABLE DRUG DELIVERY DEVICE MARKET SIZE, BY PAIN MANAGEMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL IMPLANTABLE DRUG DELIVERY DEVICE MARKET SIZE, BY PAIN MANAGEMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL IMPLANTABLE DRUG DELIVERY DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL IMPLANTABLE DRUG DELIVERY DEVICE MARKET SIZE, BY HOME CARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL IMPLANTABLE DRUG DELIVERY DEVICE MARKET SIZE, BY HOME CARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL IMPLANTABLE DRUG DELIVERY DEVICE MARKET SIZE, BY HOME CARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL IMPLANTABLE DRUG DELIVERY DEVICE MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL IMPLANTABLE DRUG DELIVERY DEVICE MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL IMPLANTABLE DRUG DELIVERY DEVICE MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL IMPLANTABLE DRUG DELIVERY DEVICE MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL IMPLANTABLE DRUG DELIVERY DEVICE MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL IMPLANTABLE DRUG DELIVERY DEVICE MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL IMPLANTABLE DRUG DELIVERY DEVICE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 85. AMERICAS IMPLANTABLE DRUG DELIVERY DEVICE MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 86. AMERICAS IMPLANTABLE DRUG DELIVERY DEVICE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 87. AMERICAS IMPLANTABLE DRUG DELIVERY DEVICE MARKET SIZE, BY DRUG ELUTING STENTS, 2018-2032 (USD MILLION)
  • TABLE 88. AMERICAS IMPLANTABLE DRUG DELIVERY DEVICE MARKET SIZE, BY INFUSION PUMPS, 2018-2032 (USD MILLION)
  • TABLE 89. AMERICAS IMPLANTABLE DRUG DELIVERY DEVICE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 90. AMERICAS IMPLANTABLE DRUG DELIVERY DEVICE MARKET SIZE, BY MICROCHIP BASED, 2018-2032 (USD MILLION)
  • TABLE 91. AMERICAS IMPLANTABLE DRUG DELIVERY DEVICE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 92. AMERICAS IMPLANTABLE DRUG DELIVERY DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 93. NORTH AMERICA IMPLANTABLE DRUG DELIVERY DEVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 94. NORTH AMERICA IMPLANTABLE DRUG DELIVERY DEVICE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 95. NORTH AMERICA IMPLANTABLE DRUG DELIVERY DEVICE MARKET SIZE, BY DRUG ELUTING STENTS, 2018-2032 (USD MILLION)
  • TABLE 96. NORTH AMERICA IMPLANTABLE DRUG DELIVERY DEVICE MARKET SIZE, BY INFUSION PUMPS, 2018-2032 (USD MILLION)
  • TABLE 97. NORTH AMERICA IMPLANTABLE DRUG DELIVERY DEVICE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 98. NORTH AMERICA IMPLANTABLE DRUG DELIVERY DEVICE MARKET SIZE, BY MICROCHIP BASED, 2018-2032 (USD MILLION)
  • TABLE 99. NORTH AMERICA IMPLANTABLE DRUG DELIVERY DEVICE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 100. NORTH AMERICA IMPLANTABLE DRUG DELIVERY DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 101. LATIN AMERICA IMPLANTABLE DRUG DELIVERY DEVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 102. LATIN AMERICA IMPLANTABLE DRUG DELIVERY DEVICE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 103. LATIN AMERICA IMPLANTABLE DRUG DELIVERY DEVICE MARKET SIZE, BY DRUG ELUTING STENTS, 2018-2032 (USD MILLION)
  • TABLE 104. LATIN AMERICA IMPLANTABLE DRUG DELIVERY DEVICE MARKET SIZE, BY INFUSION PUMPS, 2018-2032 (USD MILLION)
  • TABLE 105. LATIN AMERICA IMPLANTABLE DRUG DELIVERY DEVICE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 106. LATIN AMERICA IMPLANTABLE DRUG DELIVERY DEVICE MARKET SIZE, BY MICROCHIP BASED, 2018-2032 (USD MILLION)
  • TABLE 107. LATIN AMERICA IMPLANTABLE DRUG DELIVERY DEVICE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 108. LATIN AMERICA IMPLANTABLE DRUG DELIVERY DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 109. EUROPE, MIDDLE EAST & AFRICA IMPLANTABLE DRUG DELIVERY DEVICE MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 110. EUROPE, MIDDLE EAST & AFRICA IMPLANTABLE DRUG DELIVERY DEVICE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 111. EUROPE, MIDDLE EAST & AFRICA IMPLANTABLE DRUG DELIVERY DEVICE MARKET SIZE, BY DRUG ELUTING STENTS, 2018-2032 (USD MILLION)
  • TABLE 112. EUROPE, MIDDLE EAST & AFRICA IMPLANTABLE DRUG DELIVERY DEVICE MARKET SIZE, BY INFUSION PUMPS, 2018-2032 (USD MILLION)
  • TABLE 113. EUROPE, MIDDLE EAST & AFRICA IMPLANTABLE DRUG DELIVERY DEVICE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 114. EUROPE, MIDDLE EAST & AFRICA IMPLANTABLE DRUG DELIVERY DEVICE MARKET SIZE, BY MICROCHIP BASED, 2018-2032 (USD MILLION)
  • TABLE 115. EUROPE, MIDDLE EAST & AFRICA IMPLANTABLE DRUG DELIVERY DEVICE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 116. EUROPE, MIDDLE EAST & AFRICA IMPLANTABLE DRUG DELIVERY DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 117. EUROPE IMPLANTABLE DRUG DELIVERY DEVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 118. EUROPE IMPLANTABLE DRUG DELIVERY DEVICE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 119. EUROPE IMPLANTABLE DRUG DELIVERY DEVICE MARKET SIZE, BY DRUG ELUTING STENTS, 2018-2032 (USD MILLION)
  • TABLE 120. EUROPE IMPLANTABLE DRUG DELIVERY DEVICE MARKET SIZE, BY INFUSION PUMPS, 2018-2032 (USD MILLION)
  • TABLE 121. EUROPE IMPLANTABLE DRUG DELIVERY DEVICE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 122. EUROPE IMPLANTABLE DRUG DELIVERY DEVICE MARKET SIZE, BY MICROCHIP BASED, 2018-2032 (USD MILLION)
  • TABLE 123. EUROPE IMPLANTABLE DRUG DELIVERY DEVICE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 124. EUROPE IMPLANTABLE DRUG DELIVERY DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 125. MIDDLE EAST IMPLANTABLE DRUG DELIVERY DEVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 126. MIDDLE EAST IMPLANTABLE DRUG DELIVERY DEVICE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 127. MIDDLE EAST IMPLANTABLE DRUG DELIVERY DEVICE MARKET SIZE, BY DRUG ELUTING STENTS, 2018-2032 (USD MILLION)
  • TABLE 128. MIDDLE EAST IMPLANTABLE DRUG DELIVERY DEVICE MARKET SIZE, BY INFUSION PUMPS, 2018-2032 (USD MILLION)
  • TABLE 129. MIDDLE EAST IMPLANTABLE DRUG DELIVERY DEVICE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 130. MIDDLE EAST IMPLANTABLE DRUG DELIVERY DEVICE MARKET SIZE, BY MICROCHIP BASED, 2018-2032 (USD MILLION)
  • TABLE 131. MIDDLE EAST IMPLANTABLE DRUG DELIVERY DEVICE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 132. MIDDLE EAST IMPLANTABLE DRUG DELIVERY DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 133. AFRICA IMPLANTABLE DRUG DELIVERY DEVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 134. AFRICA IMPLANTABLE DRUG DELIVERY DEVICE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 135. AFRICA IMPLANTABLE DRUG DELIVERY DEVICE MARKET SIZE, BY DRUG ELUTING STENTS, 2018-2032 (USD MILLION)
  • TABLE 136. AFRICA IMPLANTABLE DRUG DELIVERY DEVICE MARKET SIZE, BY INFUSION PUMPS, 2018-2032 (USD MILLION)
  • TABLE 137. AFRICA IMPLANTABLE DRUG DELIVERY DEVICE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 138. AFRICA IMPLANTABLE DRUG DELIVERY DEVICE MARKET SIZE, BY MICROCHIP BASED, 2018-2032 (USD MILLION)
  • TABLE 139. AFRICA IMPLANTABLE DRUG DELIVERY DEVICE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 140. AFRICA IMPLANTABLE DRUG DELIVERY DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 141. ASIA-PACIFIC IMPLANTABLE DRUG DELIVERY DEVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 142. ASIA-PACIFIC IMPLANTABLE DRUG DELIVERY DEVICE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 143. ASIA-PACIFIC IMPLANTABLE DRUG DELIVERY DEVICE MARKET SIZE, BY DRUG ELUTING STENTS, 2018-2032 (USD MILLION)
  • TABLE 144. ASIA-PACIFIC IMPLANTABLE DRUG DELIVERY DEVICE MARKET SIZE, BY INFUSION PUMPS, 2018-2032 (USD MILLION)
  • TABLE 145. ASIA-PACIFIC IMPLANTABLE DRUG DELIVERY DEVICE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 146. ASIA-PACIFIC IMPLANTABLE DRUG DELIVERY DEVICE MARKET SIZE, BY MICROCHIP BASED, 2018-2032 (USD MILLION)
  • TABLE 147. ASIA-PACIFIC IMPLANTABLE DRUG DELIVERY DEVICE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 148. ASIA-PACIFIC IMPLANTABLE DRUG DELIVERY DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 149. GLOBAL IMPLANTABLE DRUG DELIVERY DEVICE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 150. ASEAN IMPLANTABLE DRUG DELIVERY DEVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 151. ASEAN IMPLANTABLE DRUG DELIVERY DEVICE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 152. ASEAN IMPLANTABLE DRUG DELIVERY DEVICE MARKET SIZE, BY DRUG ELUTING STENTS, 2018-2032 (USD MILLION)
  • TABLE 153. ASEAN IMPLANTABLE DRUG DELIVERY DEVICE MARKET SIZE, BY INFUSION PUMPS, 2018-2032 (USD MILLION)
  • TABLE 154. ASEAN IMPLANTABLE DRUG DELIVERY DEVICE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 155. ASEAN IMPLANTABLE DRUG DELIVERY DEVICE MARKET SIZE, BY MICROCHIP BASED, 2018-2032 (USD MILLION)
  • TABLE 156. ASEAN IMPLANTABLE DRUG DELIVERY DEVICE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 157. ASEAN IMPLANTABLE DRUG DELIVERY DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 158. GCC IMPLANTABLE DRUG DELIVERY DEVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 159. GCC IMPLANTABLE DRUG DELIVERY DEVICE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 160. GCC IMPLANTABLE DRUG DELIVERY DEVICE MARKET SIZE, BY DRUG ELUTING STENTS, 2018-2032 (USD MILLION)
  • TABLE 161. GCC IMPLANTABLE DRUG DELIVERY DEVICE MARKET SIZE, BY INFUSION PUMPS, 2018-2032 (USD MILLION)
  • TABLE 162. GCC IMPLANTABLE DRUG DELIVERY DEVICE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 163. GCC IMPLANTABLE DRUG DELIVERY DEVICE MARKET SIZE, BY MICROCHIP BASED, 2018-2032 (USD MILLION)
  • TABLE 164. GCC IMPLANTABLE DRUG DELIVERY DEVICE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 165. GCC IMPLANTABLE DRUG DELIVERY DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 166. EUROPEAN UNION IMPLANTABLE DRUG DELIVERY DEVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 167. EUROPEAN UNION IMPLANTABLE DRUG DELIVERY DEVICE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 168. EUROPEAN UNION IMPLANTABLE DRUG DELIVERY DEVICE MARKET SIZE, BY DRUG ELUTING STENTS, 2018-2032 (USD MILLION)
  • TABLE 169. EUROPEAN UNION IMPLANTABLE DRUG DELIVERY DEVICE MARKET SIZE, BY INFUSION PUMPS, 2018-2032 (USD MILLION)
  • TABLE 170. EUROPEAN UNION IMPLANTABLE DRUG DELIVERY DEVICE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 171. EUROPEAN UNION IMPLANTABLE DRUG DELIVERY DEVICE MARKET SIZE, BY MICROCHIP BASED, 2018-2032 (USD MILLION)
  • TABLE 172. EUROPEAN UNION IMPLANTABLE DRUG DELIVERY DEVICE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 173. EUROPEAN UNION IMPLANTABLE DRUG DELIVERY DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 174. BRICS IMPLANTABLE DRUG DELIVERY DEVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 175. BRICS IMPLANTABLE DRUG DELIVERY DEVICE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 176. BRICS IMPLANTABLE DRUG DELIVERY DEVICE MARKET SIZE, BY DRUG ELUTING STENTS, 2018-2032 (USD MILLION)
  • TABLE 177. BRICS IMPLANTABLE DRUG DELIVERY DEVICE MARKET SIZE, BY INFUSION PUMPS, 2018-2032 (USD MILLION)
  • TABLE 178. BRICS IMPLANTABLE DRUG DELIVERY DEVICE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 179. BRICS IMPLANTABLE DRUG DELIVERY DEVICE MARKET SIZE, BY MICROCHIP BASED, 2018-2032 (USD MILLION)
  • TABLE 180. BRICS IMPLANTABLE DRUG DELIVERY DEVICE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 181. BRICS IMPLANTABLE DRUG DELIVERY DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 182. G7 IMPLANTABLE DRUG DELIVERY DEVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 183. G7 IMPLANTABLE DRUG DELIVERY DEVICE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 184. G7 IMPLANTABLE DRUG DELIVERY DEVICE MARKET SIZE, BY DRUG ELUTING STENTS, 2018-2032 (USD MILLION)
  • TABLE 185. G7 IMPLANTABLE DRUG DELIVERY DEVICE MARKET SIZE, BY INFUSION PUMPS, 2018-2032 (USD MILLION)
  • TABLE 186. G7 IMPLANTABLE DRUG DELIVERY DEVICE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 187. G7 IMPLANTABLE DRUG DELIVERY DEVICE MARKET SIZE, BY MICROCHIP BASED, 2018-2032 (USD MILLION)
  • TABLE 188. G7 IMPLANTABLE DRUG DELIVERY DEVICE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 189. G7 IMPLANTABLE DRUG DELIVERY DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 190. NATO IMPLANTABLE DRUG DELIVERY DEVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 191. NATO IMPLANTABLE DRUG DELIVERY DEVICE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 192. NATO IMPLANTABLE DRUG DELIVERY DEVICE MARKET SIZE, BY DRUG ELUTING STENTS, 2018-2032 (USD MILLION)
  • TABLE 193. NATO IMPLANTABLE DRUG DELIVERY DEVICE MARKET SIZE, BY INFUSION PUMPS, 2018-2032 (USD MILLION)
  • TABLE 194. NATO IMPLANTABLE DRUG DELIVERY DEVICE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 195. NATO IMPLANTABLE DRUG DELIVERY DEVICE MARKET SIZE, BY MICROCHIP BASED, 2018-2032 (USD MILLION)
  • TABLE 196. NATO IMPLANTABLE DRUG DELIVERY DEVICE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 197. NATO IMPLANTABLE DRUG DELIVERY DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 198. GLOBAL IMPLANTABLE DRUG DELIVERY DEVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 199. UNITED STATES IMPLANTABLE DRUG DELIVERY DEVICE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 200. UNITED STATES IMPLANTABLE DRUG DELIVERY DEVICE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 201. UNITED STATES IMPLANTABLE DRUG DELIVERY DEVICE MARKET SIZE, BY DRUG ELUTING STENTS, 2018-2032 (USD MILLION)
  • TABLE 202. UNITED STATES IMPLANTABLE DRUG DELIVERY DEVICE MARKET SIZE, BY INFUSION PUMPS, 2018-2032 (USD MILLION)
  • TABLE 203. UNITED STATES IMPLANTABLE DRUG DELIVERY DEVICE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 204. UNITED STATES IMPLANTABLE DRUG DELIVERY DEVICE MARKET SIZE, BY MICROCHIP BASED, 2018-2032 (USD MILLION)
  • TABLE 205. UNITED STATES IMPLANTABLE DRUG DELIVERY DEVICE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 206. UNITED STATES IMPLANTABLE DRUG DELIVERY DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 207. CHINA IMPLANTABLE DRUG DELIVERY DEVICE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 208. CHINA IMPLANTABLE DRUG DELIVERY DEVICE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 209. CHINA IMPLANTABLE DRUG DELIVERY DEVICE MARKET SIZE, BY DRUG ELUTING STENTS, 2018-2032 (USD MILLION)
  • TABLE 210. CHINA IMPLANTABLE DRUG DELIVERY DEVICE MARKET SIZE, BY INFUSION PUMPS, 2018-2032 (USD MILLION)
  • TABLE 211. CHINA IMPLANTABLE DRUG DELIVERY DEVICE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 212. CHINA IMPLANTABLE DRUG DELIVERY DEVICE MARKET SIZE, BY MICROCHIP BASED, 2018-2032 (USD MILLION)
  • TABLE 213. CHINA IMPLANTABLE DRUG DELIVERY DEVICE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 214. CHINA IMPLANTABLE DRUG DELIVERY DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)